SOAT1 and sarcoidosis: Similarly, our findings in sarcoidosis CD4 naïve T cells suggest they may be effectively targeted by nintedanib, a multi-tyrosine kinase inhibitor approved for use in idiopathic pulmonary fibrosis that targets the JAK/STAT pathway and reduces the effects of TGFβ signaling (54).